Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Sargramostim for Respiratory Virus-Associated Severe Pneumonia (iGRASP)
NCT02601365Phase 1Withdrawn
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Mar 2019
- Primary completion
- May 2019
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label, single-arm trial of sargramostim in viral pneumonia and acute respiratory distress syndrome (ARDS), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoint: Treatment-Emergent Adverse Events at 1 year. Planned start Mar 2019; status: withdrawn.
02
Drugs
sargramostim
03
Conditions
viral pneumoniaacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT02601365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02601365.